Ironwood Featured Presentations Save

Ironwood Pharmaceuticals, Inc. (IRWD) today announced one oral and twelve poster presentations to be presented at the upcoming ACR/ARHP Annual Meeting in San Diego, California from November 3-8, 2017. The meeting is hosted by the American College of Rheumatology and Association of Rheumatology Health Professionals.

The presentations include a poster entitled, “Less Than Half of Patients Treated with High-Dose Allopurinol Reach Serum Uric Acid Target,” which includes data from a quantitative survey of rheumatologists and primary care physicians in the U.S. and E.U. to assess the proportion of patients with gout on allopurinol alone who fail to reach serum uric acid (sUA) target levels. The researchers concluded that less than 50% of patients achieved sUA <6 mg/dL at any dose of allopurinol, and those on a higher dose of allopurinol were not more likely to reach this target.

“Data to be presented at ACR reinforce the high unmet need in uncontrolled gout, with an estimated two million patients in the U.S. taking allopurinol alone who are not achieving target serum uric acid levels,” said Christopher Wright, MD, PhD, senior vice president of global development and chief development officer at Ironwood. “Ironwood is pleased to be able to provide physicians with a new treatment option, DUZALLO® (lesinurad and allopurinol), the first and only medicine available for appropriate patients with gout that treats high uric acid in two ways with one pill. We feel it is an important option for them to consider as they evaluate and treat adult patients with uncontrolled gout.”

Other presentations to be given at ACR address the long-term health consequences of gout and the association of uncontrolled gout on diabetes, heart failure and chronic kidney disease.

The titles and scheduled presentation times are as follows:

• Less Than Half of Patients Treated with High-Dose Allopurinol Reach Serum Uric Acid Target (abstract #1120, poster), to be presented during the Metabolic and Crystal Arthropathies Poster I on Monday, Nov. 6, 2017, 9:00 a.m. – 11:00 a.m. Eastern Time, by Douglas C.A. Taylor, MBA, Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA.
• Allopurinol Treatment for Gout: How Long to Reach Serum Urate Goal? (abstract #1121, poster), to be presented during the Metabolic and Crystal Arthropathies Poster I on Monday, Nov. 6, 2017, 9:00 a.m. – 11:00 a.m. Eastern Time, by Jean J. Lim, DrPH, Tufts University School of Medicine, Boston, MA; Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA.
• Allopurinol Dose-Titration Patterns Relative to Serum Uric Acid Levels in Gout Patients: US Electronic Health Record Data (abstract #2059, poster), to be presented the Metabolic and Crystal Arthropathies Poster II on Tuesday, Nov. 7, 2017, 9:00 a.m. – 11:00 a.m. Eastern Time, by An Chen Fu, MS, Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA.
• Uncontrolled Gout Patients with Higher Heart Failure Hospitalization Rates in US (abstract #1119, poster), to be presented during the Metabolic and Crystal Arthropathies Poster I on Monday, Nov. 6, 2017, 9:00 a.m. – 11:00 a.m. Eastern Time, by Robert Morlock, PhD, YourCareChoice, Ann Arbor, MI, USA.
• Diabetes and Gout: Real-World Evidence Evaluating Patient Characteristics, Treatment Patterns, and Healthcare Utilization(abstract #1118, poster), to be presented during the Metabolic and Crystal Arthropathies Poster I on Monday, Nov. 6, 2017, 9:00 a.m. – 11:00 a.m. Eastern Time, by Douglas C.A. Taylor, MBA, Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA.
• Prevalence of Chronic Kidney Disease and Uncontrolled Serum Uric Acid Levels in US Adult Gout Population: Results from the National Health and Nutrition Examination Survey 2007–2012 (abstract #1122, poster), to be presented during the Metabolic and Crystal Arthropathies Poster I on Monday, Nov. 6, 2017, 9:00 a.m. – 11:00 a.m. Eastern Time, by Jean J. Lim, DrPH, Tufts University School of Medicine, Boston, MA; Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA.
• Determinants of Patient and Physician Disagreement on Presence of a Gout Flare (abstract #357, poster), to be presented during the Patient Outcomes, Preferences, and Attitudes Poster I on Sunday, Nov. 5, 2017, 9:00 a.m. – 11:00 a.m. Eastern Time, by Aprajita Jagpal, MD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
• Patients with Gout Consider Zero Flares over the Previous Six or Twelve Months Necessary for a Remission State (abstract #350, poster), to be presented during the Patient Outcomes, Preferences, and Attitudes Poster I on Sunday, Nov. 5, 2017, 9:00 a.m. – 11:00 a.m. Eastern Time, by Angelo L. Gaffo, MD, MsPH, Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA
• Low and Moderate Intensity Exercise Suppresses Inflammatory Responses and Suggests Therapeutic Efficacy in an Acute Mouse Model of Gout (abstract #60, poster), to be presented during the Biology and Pathology of Bone and Joint Poster I on Sunday, Nov. 5, 2017, 9:00 a.m. – 11:00 a.m. Eastern Time, by Nicholas A. Young,PhD, Department of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
• A Genome-Wide Association Study of Gout in People of European Ancestry (abstract #1104, poster), to be presented during the Metabolic and Crystal Arthropathies Poster I on Monday, Nov. 6, 2017, 9:00 a.m. – 11:00 a.m. Eastern Time, by Tony R. Merriman, PhD, Department of Biochemistry, University of Otago, New Zealand.
• Identification of Urate Deposits in Patients with Asymptomatic Hyperuricemia using a Dual-Energy CT Scan (abstract #2057, poster), to be presented during the Metabolic and Crystal Arthropathies Poster II on Tuesday, Nov. 7, 2017, 9:00 a.m. - 11:00 a.m. Eastern Time, by Penny Wang, Clinical Research Assistant, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, USA.
• Validation of a Definition for Flare in Patients with Established Gout(abstract #2950, poster), to be presented during the Patient Outcomes, Preferences, and Attitudes III on Wednesday, Nov. 8, 2017, 11:00 a.m. – 12:30 p.m. Eastern Time, by Angelo L. Gaffo, MD, MsPH, Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
• Human Cartilage Influences the Crystallization of Monosodium Urate (MSU); Understanding the Link between Gout and Osteoarthritis(abstract #2896, oral presentation), to be presented during the Metabolic and Crystal Arthropathies II: Mechanisms of Crystal Inflammation and Metabolism on Wednesday, Nov. 8, 2017, 9:00 a.m. – 10:30 a.m. Eastern Time, by Nicola Dalbeth, MBChB MD FRACP, University of Auckland, Auckland, New Zealand.